AIDS vaccine focus shifts after disappointments
By Andrew Quinn
WASHINGTON (Reuters) - A global AIDS vaccine conference this week will seek fresh strategies against the HIV virus, with experts weighing the value of basic laboratory research against large-scale human clinical trials after a string of disappointments.
Approaches focusing on “neutralizing antibodies” that would allow the human immune system to block infection completely, are likely to take precedence over existing models that seek to manage infection after it occurs, experts said.
“There’s a real redirection and rethinking,” said Lynn Morris, co-chair of a world AIDS vaccine conference that starts in Cape Town, South Africa, on Monday.
“Fundamentally we don’t understand enough about the human immune system and we don’t know how the immune system deals with HIV.”
The conference — a gathering of many of the top names in HIV research — follows a year that saw scientists drop plans for widespread human testing of the two most promising vaccine prototypes due to safety concerns.
The AIDS virus infects an estimated 33 million people globally and has killed 25 million since it was identified in the 1980s. Cocktails of drugs can control the virus but there is no cure.
The two stalled vaccines, one developed by drug giant Merck and the other by U.S. government researchers, both aimed to fight AIDS by encouraging so-called cell-mediated immunity, jump-starting T-cells to tackle the virus and stop or slow the progress of HIV-related disease.
But early results from a large human trial of the Merck product were discouraging and data showed the vaccine may have left some people more prone to HIV infection — halting the tests and prompting some scientists to reconsider the model. Continued…
--------------------------------------------------------------------------------------------Related Posts:
By Wendell Roelf CAPE TOWN (Reuters) - A U.S. recession could cut AIDS funding and impede the drive to find a vaccine for the disease, a senior official with a group spearheading vaccine research said on Tuesday. The United States is the center of AIDS vaccine research. Its government contributed $659 million, or 69 percent of the
Full Post: U.S. downturn could hurt AIDS vaccine drive: group
--------------------------------------------------------------------------------------------
By Laura MacInnis GENEVA (Reuters) - The body’s initial response to contracting HIV could provide the answers scientists need to develop a vaccine for the AIDS-causing virus, a Nobel-winning expert said on Monday. The AIDS epidemic has killed about 25 million people, and about 33 million worldwide are now infected with HIV. Cocktails of drugs can control
Full Post: First days after HIV infection may hold vaccine key
--------------------------------------------------------------------------------------------
By Adam Cox STOCKHOLM (Reuters) - A French scientist who shared this year’s Nobel prize for medicine said on Saturday he believed the transmission of AIDS could be eliminated within years. Luc Montagnier, director of the World Foundation for AIDS Research and Prevention, told a news conference together with this year’s other winners for medicine that halting
Full Post: Nobel winner sees end to AIDS spread within years
--------------------------------------------------------------------------------------------
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Genetically engineered immune cells can spot the AIDS virus even when it tries to disguise itself, offering a potential new way to treat the incurable infection, researchers reported on Sunday. The killer T-cells, dubbed “assassin” cells, were able to recognize other cells infected by HIV and slow
Full Post: Souped-up immune cells catch even disguised HIV
--------------------------------------------------------------------------------------------
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - A vaccine designed to protect women and girls from cervical cancer caused by a wart virus may protect men, too, maker Merck and Co reported on Thursday. The Gardasil vaccine was 90 percent effective in preventing lesions, mostly sexually transmitted warts, caused by the virus in men,
Full Post: Merck vaccine protects men from wart virus, too